- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 639-653 of
1,261 results
2522 Exhibit: EX2522 Novo Nordisk, Ozempic semaglutide injection 05 mg, 1 mg, o...
Document
IPR2023-00724, No. 2522 Exhibit - EX2522 Novo Nordisk, Ozempic semaglutide injection 05 mg, 1 mg, or 2 mg WAC Price, httpswwwnovopricingcomozempichtml, last updated Oct 2023 (P.T.A...
|
|
Cite Document
2050 Exhibit: EX2050 Declaration of Christine B Jensen, MD, PhD {REDACTED
Document
IPR2023-00724, No. 2050-2 Exhibit - EX2050 Declaration of Christine B Jensen, MD, PhD {REDACTED (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2482 Exhibit: EX2482 Novo Nordisk, “Possible Side Effects of Ozempic® semaglutid...
Document
IPR2023-00724, No. 2482-2 Exhibit - EX2482 Novo Nordisk, “Possible Side Effects of Ozempic® semaglutide Injection,” httpswwwozempiccomhow to takeside effectshtml (P.T.A.B. Jan. 17, 2024...
|
|
Cite Document
2409 Exhibit: EX2409 Victoza® Prescribing Information rev Aug 2017
Document
IPR2023-00724, No. 2409 Exhibit - EX2409 Victoza® Prescribing Information rev Aug 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2428 Exhibit: EX2428 Kazano® Prescribing Information rev Feb 2017
Document
IPR2023-00724, No. 2428 Exhibit - EX2428 Kazano® Prescribing Information rev Feb 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2051 Exhibit: EX2051 Declaration of Anne Flint, Ph D REDACTED
Document
IPR2023-00724, No. 2051-2 Exhibit - EX2051 Declaration of Anne Flint, Ph D REDACTED (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2395 Exhibit: EX2395 Byetta® Prescribing Information rev Feb 2015
Document
IPR2023-00724, No. 2395 Exhibit - EX2395 Byetta® Prescribing Information rev Feb 2015 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2447 Exhibit: EX2447 US Food Drug Administration, DrugsFDA, Trulicity®
Document
IPR2023-00724, No. 2447 Exhibit - EX2447 US Food Drug Administration, DrugsFDA, Trulicity® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2481 Exhibit: EX2481 FDA Approves Ozempic semaglutide for Cardiovascular Risk...
Document
IPR2023-00724, No. 2481 Exhibit - EX2481 FDA Approves Ozempic semaglutide for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease, httpswwwdrugscom...
|
|
Cite Document
2421 Exhibit: EX2421 US Food Drug Administration, DrugsFDA, Bydureon® BCISE™
Document
IPR2023-00724, No. 2421 Exhibit - EX2421 US Food Drug Administration, DrugsFDA, Bydureon® BCISE™ (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2014 Exhibit: EX2014 Weeda, E, et al, “Medication adherence to injectable glucago...
Document
IPR2023-00724, No. 2014 Exhibit - EX2014 Weeda, E, et al, “Medication adherence to injectable glucagon like peptide 1 GLP 1 receptor agonists dosed once weekly vs once daily in patients wit...
|
|
Cite Document
2512 Exhibit: EX2512 Novo Nordisk, Financial report for the period 1 January 2022...
Document
IPR2023-00724, No. 2512 Exhibit - EX2512 Novo Nordisk, Financial report for the period 1 January 2022 to 30 September 2022 Nov 2, 2022 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2389 Exhibit: EX2389 Ho, PM, Bryson, CL, and Rumsfeld, JS, Medication Adheren...
Document
IPR2023-00724, No. 2389 Exhibit - EX2389 Ho, PM, Bryson, CL, and Rumsfeld, JS, Medication Adherence, Circulation, 2009 119233028 3035 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2435 Exhibit: EX2435 US Food Drug Administration, DrugsFDA, Farxiga®
Document
IPR2023-00724, No. 2435 Exhibit - EX2435 US Food Drug Administration, DrugsFDA, Farxiga® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2402 Exhibit: EX2402 US Food Drug Administration, DrugsFDA, Janumet® XR
Document
IPR2023-00724, No. 2402 Exhibit - EX2402 US Food Drug Administration, DrugsFDA, Janumet® XR (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
